Arcoxia FDA Approval Status

FDA Approved: No
Brand name: Arcoxia
Generic name: etoricoxib
Company: Merck
Treatment for: Osteoarthritis

Arcoxia (etoricoxib) is a selective COX-2 inhibitor for treatment of osteoarthritis.

In April 2007, Merck & Co., Inc. announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for Arcoxia (etoricoxib) had not been approved.

Development timeline for Arcoxia

Date	Article
Apr 27, 2007	Merck Receives Non Approvable Letter from FDA for Arcoxia(etoricoxib)
Apr 13, 2007	Public Citizen: FDA Should Not Approve "Offspring of Vioxx" Painkiller
Apr 12, 2007	FDA Advisory Committee Recommends Against Approval for Merck's NDAfor Arcoxia (etoricoxib)
Apr 11, 2007	Statement by Merck & Co., Inc. Regarding FDA Arthritis Drugs Advisory Committee Meeting on Arcoxia (etoricoxib)
Apr 9, 2007	Arthritis Foundation Chief Public Health Officer Testifies at FDA Hearing on Arcoxia
Nov 10, 2006	Merck Responds to FDA-Issued Approvable Letters for Arcoxia (etoricoxib)
Jun 17, 2005	Merck Provides Status Update on Ongoing Arcoxia Trials
Oct 29, 2004	Merck Receives ’Approvable’ Letter for Arcoxia

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer